English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Hematopoietic cell‑specific protein 1‑associated protein X‑1 (HAX‑1) has been found to be involved in several types of cancer. However, the role of HAX‑1 in CRC remains to be elucidated. The aim of the present study was to investigate whether the expression of HAX‑1 is associated with the progression of CRC, and to determine the effects of HAX‑1 on the apoptosis and proliferation of CRC cells. Tumor tissues and adjacent noncancerous tissues were collected from 60 patients with CRC, following the provision of informed consent. The expression levels of HAX‑1 and the association with clinical and pathological characteristics were then analyzed. The expression levels of HAX‑1 were significantly higher in the cancerous tissues from the patients with CRC, particularly in tissues of an advanced stage of cancer. In addition, HAX‑1 expression was associated with malignant progression and poor prognosis. Furthermore, SW480 CRC cells, overexpressing HAX‑1, exhibited increased resistance to camptothecin in vitro, and promoted proliferation in vitro and in vivo. By contrast, HAX‑1 knockdown significantly decreased the proliferation. In addition, the expression levels of ki‑67 and phosphorylated‑akt were inhibited following HAX‑1 knockdown. In conclusion, the expression levels of HAX‑1 were increased in cancerous tissue from patients with CRC, and were associated with progression of the disease. These results suggested that HAX‑1 may contribute to chemotherapy resistance and malignant progression in CRC.

Expression of HAX-1 in colorectal cancer and its role in cancer cell growth